Stay updated on Optimal Tenecteplase Dose in Stroke Clinical Trial
Sign up to get notified when there's something new on the Optimal Tenecteplase Dose in Stroke Clinical Trial page.

Latest updates to the Optimal Tenecteplase Dose in Stroke Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation related to the EXTEND-IA TNK Part 2 randomized clinical trial, which included a list of investigators and details about the study's findings.SummaryDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant updates regarding the trial design and treatment protocols for ischemic stroke patients, including the introduction of a new revision version and changes to the administration of intravenous tenecteplase.SummaryDifference26%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Optimal Tenecteplase Dose in Stroke Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Optimal Tenecteplase Dose in Stroke Clinical Trial page.